source
- Genentech signs $1.5 billion bispecific antibody deal with Earendil LabsGenentech, Roche's US subsidiary, announced a licensing agreement with Earendil Labs to discover and develop multiple bispecific antibodies aimed at oncology. The agreement provides a $55 million…
- Biomanufacturers Redesign Processes to Blend Emergency Vaccine Readiness with Commercial FlexibilityManufacturers are overhauling their production methods to simultaneously improve rapid vaccine deployment for future health crises and maintain flexible, commercially viable manufacturing networks…